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HIGHLIGHTS 
  TNF-α, TNF-β, IFN-γ, IL-4 increase in First Episode Psychosis 
  IL-4 increase in Ultra High Risk state 
 No deviation in cortisol and IGF-1 in FEP and UHR states 
 
 
 
 
 
 
 
ABSTRACT 
The aim of the study was to determine circulating cytokines, cortisol and Insulin-like 
Growth Factor (IGF)-1, known for their involvement in inflammation, in male 
patients with First Episode Psychosis (FEP) and subjects at Ultra High Risk (UHR) for 
Psychosis. The FEP group presented increased pro-inflammatory cytokines (TNF-α, 
IFN-γ, ΤNF-β) as well as increased anti-inflammatory cytokine (IL-4) compared with 
Healthy Controls (HC). The UHR group showed increased IL-4 against HC. In contrast, 
none of the groups did show deviation from normality in either cortisol or IGF-1 
levels. These preliminary findings support the cytokines’ role in the inflammatory 
hypothesis in psychosis. 
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1.Introduction 
In recent years, the interest of the scientific community in the detection and 
validation of potential biomarkers regarding the diagnostic validity, prediction of 
outcome and delineation of causative mechanisms in psychosis, has been increasing. 
The research that is relevant to the investigation of the inflammatory substrate in 
psychosis involves the evaluation of immune cells, neurotrophic factors and stress 
hormones. Respectively, cytokines, Insulin like Growth Factor (IGF)-1 and cortisol 
have attracted the bulk of the attention lately. Reviews of the circulating cytokines 
(Drzyzga et al., 2006) and Hypothalamo-Pituitary-Adrenal (HPA) axis function 
(Bradley and Dinan, 2010) in chronic medicated patients with psychosis, posed 
heterogeneity in demographic and clinical factors as the explanation for the 
inconclusive results. Thus, reviews of studies on cytokines (Upthegrove et al., 2014) 
and cortisol in First Episode Psychosis (FEP) (Karanikas et al., 2014) and Ultra High 
Risk (UHR) (Karanikas and Garyfallos, 2015) for psychosis subjects emerged, 
suggesting a number of theories (Drexhage et al., 2011; Müller and Schwarz, 2010; 
Smith and Maes, 1995), regarding the immune alterations as well as upregulation of 
cortisol secretion proximal to the full blown FEP. In regard to IGF-1, albeit its known 
neuroprotective and antiapoptotic properties (Dore et al., 1997), the evidence for its 
role in psychosis remains controversial (Palomino et al., 2013; Venkatasubramanian 
et al., 2010). Furthermore, research has hinted at the interplay among IGF-1, cortisol 
and cytokines; IGF-1 levels could be influenced by cortisol (Cianfarani et al., 1998), 
pro-inflammatory cytokines could activate the HPA axis and glucocorticoids inhibit 
the pro-inflammatory cytokines’ secretion (Chrousos, 2000). To our knowledge no 
study has incorporated the simultaneous evaluation of these parameters in FEP and 
UHR states. Thus, we aimed to test the hypothesis for increased pro-inflammatory 
cytokines[(IL-1, IL-6, Tumor Necrosis Factor-α, TNF, of the innate immunity), 
(Interferon-γ, IFN, IL-2, IL-8, IL-12p70, TNF-β of the T helper-1, Th-1, immune 
response of the adaptive immunity)] and decreased anti-inflammatory ones (IL-4, IL-
5, IL-6, IL-10 of the Th-2 immune response of the adaptive immunity), as well as 
increased cortisol and decreased IGF-1 in serum of male FEP patients compared to 
Healthy Controls (HC). We also attempted to validate the presumption of deviation 
from normality of those factors in a cohort at UHR state. 
2.Methods 
2.1. Subjects 
The study was conducted from May 2012 up until May 2014, within the setting of 
the Psychiatric Department of the 424 General Military Hospital of Thessaloniki, 
Greece.  The recruitment of the FEP group involved 25 male patients with their first 
presentation of psychotic episode without affective features. Drug induced psychosis 
was excluded, based on the history, clinical presentation and urine drug test. Both 
the FEP group and the UHR group (N=12 males) consisted of military personnel who 
were referred for further evaluation of their change/deterioration in their behavior 
and/or function. In addition, we included 23 male volunteer participants, coming 
from the Hospital’s staff, as HC.  
2.2. Clinical assessment     
2.2.1. Clinical Diagnoses  
FEP was defined as the presence of daily psychotic symptoms longer than a week 
according to the Melbourne group’s Personal Assessment and Crisis Evaluation 
(PACE) Criteria (Yung et al., 1998). Diagnoses of the FEP patients were confirmed 
with the application of the Structured Clinical Interview (SCID) for DSM-IV-TR (First et 
al., 2002). Regarding the UHR group, their recruitment was based on the PACE 
criteria using the Comprehensive Assessment of At Risk Mental States (CAARMS) 
(Yung et al., 2005). According to the pre mentioned classification,  UHR individuals 
must meet at least one of the following constellations of criteria: (a) Attenuated 
Psychotic Symptoms (APS); denoting the experience of sub threshold positive 
psychotic symptoms during the past year; (b) Brief Limited Intermittent Psychotic 
Symptoms (BLIPS); the experience of episodes of frank psychotic symptoms that 
have not lasted longer than a week and have been self-remitting; or (c) Trait and 
State Risk Factor; having a first degree relative with a psychotic disorder or the 
identified subject has been diagnosed with Schizotypal Personality Disorder (SPD) 
plus a significant decrease in functioning during the previous year. No subject was 
diagnosed with comorbid psychiatric states. Finally, psychiatric morbidity was 
excluded within the HC subjects (SCID-Non Patient) and it was confirmed that they 
did not have any first degree relatives diagnosed with psychosis. All diagnoses were 
performed by 2 qualified senior psychiatrists (E.K. and E.N.), subject to 
comprehensive training and inter rater reliability testing (κ = 0.9). 
2.2.2. Psychopathology severity 
We assessed symptom severity in FEP and UHR patients with the Greek version of 
the Positive and Negative Syndrome Scale (PANSS) (Lykouras et al., 1994). The 
results were calculated as PANSS Positive Factor (PF), Negative Factor (NF), General 
Psychopathology (GP) and Total score (TOTAL).  
2.3. Other Inclusion-exclusion criteria    
We included FEP subjects who were medication naïve or minimally treated; the later 
meaning that, depending on their clinical presentation, they should not have been 
for more than 3 days on any type of psychotropic medication (antipsychotic, mood 
stabilizer, antidepressant, benzodiazepines) up until all blood sampling had been 
completed. The UHR participants needed to be drug naïve to be included in the 
study. 
All the participants were physically healthy with no signs of active inflammation for 
at least 15 days prior to the study -based on the medical history, physical clinical 
examination and laboratory investigations. They were aged between 18-40, with 
BMI<30, without intellectual disability, neither shift work. Any illicit psychotropic 
drug users were excluded; this was ensured through history taking and urine drug 
tests. Participants with any chronic medical state (including but not restricted to 
impaired thyroid function, polydipsia, asthma, diabetes, chronic fatigue, 
autoimmune disorders) or medication that could impair the immunological, 
endocrinological or neurological status were excluded as well.  
All participants gave informed consent. The study was approved by the local ethical 
committee of the hospital and performed in accordance with the latest edition of 
the Declaration of Helsinki. 
2.4. Blood Analyses  
The day 1 of blood sampling, samples were collected at 3 separate points in time; 
08:00, 12:00 and 18:00. Cortisol was measured from the 3 samples at day 1 with 
Radioimmunoassay using the DIA source CORTISOL-RIA-CT Kit manufactured by DIA 
source ImmunoAssays S.A. Rue du Bosquet, 2, B-1348 Louvain-la-Neuve, Belgium. 
The cytokines were measured based on the principles of Fluorescent Bead 
Immunoassay and the Flow Cytomix. The kits used were the Flowcytomix Human 
Th1/Th2 11plexKit  (IFN-γ, IL-1b,IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12p70, TNF- α, TNF-
β) BMS 810FF and the Flow Cytomix BMS 82017FF human IL- 17A simplex kit of the 
Bender MedSystems GmbHCampus Vienna Biocenter2, A-1030 Vienna, Austria.The 
method used for the IGF-1 evaluation involved the Eliza Immunoassay and the kit 
was the Mediagnost IGF-I-ELISA E20, Germany. The manufacturers’ instructions were 
followed. Serum for measurement of both IGF-1 and cytokines was collected from 
day 1 at 08:00, thawed, stored and measured simultaneously. 
2.5. Statistical analysis  
Statistical analyses were performed using SPSS 20 software. The cortisol values were 
assessed with the formula of  ‘Area Under Curve with respect to ground’ (cort-AUCg) 
(Pruessner et al., 2003). All cytokine and IGF-1 values were logarithmically 
transformed. Multi-group differences were assessed by way of the Kruskal-Wallis 
test, individual group differences against the HC were assessed by way of Mann-
Whitney tests with the p value corrected for multiple comparisons using the 
Bonferroni correction, target p set at <0.025 for an alpha of <0.05.  Intra-group 
correlations were assessed with the Spearman rs statistic.  
3. Results 
Groups’ demographics and clinical data are presented in Table 1. Four FEP group 
patients were diagnosed with Brief Psychotic Disorder, 16 with Schizophreniform 
Disorder,1 with Schizophrenia and 4 with Psychotic Disorder Not Otherwise 
Specified. The mean (±SD) Duration of their Untreated Psychosis (DUP) was 
estimated to be 14.8(±6.3) weeks. Similarly, 8 UHR individuals presented with APS, 2 
with BLIPS and 2 were diagnosed with SPD plus functional deterioration during the 
past year. Eight (32%) out of 25 FEP patients were under treatment (risperidone, 
olanzapine, quetiapine, haloperidol) for a mean of 1.75±0.8 days. The mean daily 
Chlorpromazine equivalent dose was 555.3±388 mg. All the UHR subjects were drug 
naïve. The demographic parameters, shown in Table 1, did not differ significantly 
among the groups (all p>0.05) and along with the medication and DUP parameters of 
the FEP only group, did not correlate with the cortisol levels nor with the cytokines 
and IGF-1 levels (all p>0.05); thus they were not controlled as confounders. 
The FEP group showed significantly higher concentrations of TNF-α (z=-2.374, 
p=0.018), TNF-β (z=-2.379, p=0.018), IFN-γ (z=-2.343, p=0.020), IL-4 (z=-2.552, 
p=0.011) compared with the HC group.The UHR group exhibited a significant 
increase of IL-4 compared with the HC group (z=-2.591, p=0.010), Figure 1. 
Within the FEP group, TNF-α positively correlated with IFN-γ (rho=+0.76, p<0.001) 
and IL-4 (rho=+0.58, p=0.002) andsimilarly IFN-γ with IL-4 (rho=+0.72, p<0.001). 
Within the UHR group, IL-4 was not associated with the rest of cytokines. No 
significant correlations (all p>0.05) were demonstrated among the cytokines, IGF-1, 
cort-AUCg and psychopathology within each ofthe FEP and UHR groups. 
4. Discussion 
The FEP group showed significantly increased levels of serum TNF-α, TNF-β, IFN-γ 
and IL-4 levels compared to HC, thus suggesting activation of different branches of 
immunity with the emergence of full blown psychosis. The UHR group presented 
increased IL-4 levels against the HC, confirming the presumption of immune 
alterations even from the prodromal stage. The results concerning the HPA axis 
function, showed that neither the FEP nor the UHR group did reach a significant 
deviation from the HC. Finally, none of the FEP and UHR groups did show significant 
change in serum IGF-1 levels compared with the HC. 
The increased levels of TNF-α and IFN-γ in our FEP group, lie in partial agreement 
with both Miller et al.’s (2011) meta-analysis which attributed to them a trait marker 
role and Upthegrove et al.’s (2014) meta-analysis of drug naïve FEP studies which 
suggested high effect size for elevated TNF-α but not for IFN-γ. The deviation of TNF-
a along with cytokines from the Th-1 immune response of the adaptive immunity, 
such as IFN-γ and TNF-β, in our FEP group, could imply the activation of a pro-
inflammatory process, thus confirming our testing hypothesis, which stands 
congruent with the Smith and Maes’s(1995) theory of a synchronous activation of 
the innate and Th-1 response of the adaptive arm of immunity in psychosis.This 
presumption is further supported by the significant positive associations between 
TNF-α (innate immunity) and IFN-γ (Th-1 cytokine of the adaptive arm) shown only 
by our FEP group. Notably, our study suggests a significant role for another pro-
inflammatory cytokine, TNF-β, whose role in psychosis has hitherto minimally been 
investigated.  
Regarding IL-4, its concentration was increased in the FEP group compared with the 
HC. This finding lies against our initial hypothesis. Interestingly, IL-4 was the only 
cytokine exhibiting increased levels in the UHR group in relation to the HC. 
Consequently, a mobilization of IL-4 in serum in both the FEP and UHR groups could 
be speculated. This increase of IL-4 could possibly be explained by its role in the 
activation of the Th-2 immune response and its consequent anti-inflammatory 
action. Conversely viewing, the increased IL-4 levels in both the FEP and UHR groups 
against HC, could be interpreted as etiological factor instead of compensatory 
neuroprotective state. In that case, Müller and Schwarz’s (2010) aetiopathogenetic 
hypothesis of a Th-2 shift could be substantiated. Unfortunately, the cross sectional 
design of the study did not allow evaluation of the conversion ratio of the UHR 
subjects to psychotic patients, thus precluding any firm conclusions about the role of 
IL-4’s increase in relation to the etiological substrate, pathophysiological sequence, 
the etiological vs compensatory nature and the existence of any potential link to a 
biological endophenotype of the psychotic trajectory (Nasrallah et al., 2011). 
Contrary to our prediction, neither the FEP group nor the UHR subjects did exhibit 
clear evidence for cortisol increase in relation to the HC. This finding appears to 
deviate from the speculation of an up regulation of cortisol secretion during FEP 
(Karanikas et al., 2014) and even earlier at prodrome (Karanikas and Garyfallos, 
2015). Yet, despite the fact that our groups were matched for gender, age, BMI, 
smoking, education-which was not the case for the majority of the reviewed studies- 
plus they were only minimally exposed to medication; the sample size was small and 
the diagnoses provisional and subject to change prospectively. The later reflects the 
diverse pathways from ‘genome to the phenome’, which in turn may relate to the 
phenotypic, pathophysiologic and etiological heterogeneity of psychosis (Nasrallah 
et al., 2011). Should an inadequacy/deficit of the HPA axis function to change/adapt 
to the increase of the pro-inflammatory cytokines of both the innate (TNF-α) and the 
adaptive (IFN-γ, TNF-β) immunity arms, is the case in our FEP patients, as evidenced 
by the non-deviation of circulating cortisol, then a deficit of the stress system to 
preserve homoeostasis could be speculated. Again, it is premature to hypothesize 
whether this non deviation of the HPA axis function as well as our findings regarding 
the circulating cytokines’ levels, constitute a link to etiology or on the chain of 
pathophysiology, are compensatory, a consequence, or an epiphenomenon. 
Finally, the non-deviation of IGF-1 in the FEP cohort of the present study lies in 
agreement with other studies (Palomino et al., 2013) but contrasts others which 
either support decrease (Venkatasubramanian  et al., 2010) or increase (Lee and 
Kim, 2007) of circulating IGF-1 in patients with psychosis compared with HC. The 
discrepancy of the results among the aforementioned studies (ours included) could 
be attributed to the heterogeneity of the participant groups in terms of diagnoses 
[Schizophrenia alone (Lee and Kim, 2007; Venkatasubramanian et al., 2010) vs mixed 
Schizophrenia and Bipolar Disorder (Palomino et al., 2013) vs newly diagnosed FEP 
with only 1 Schizophrenia subject (ours)], medication status [naïve 
(Venkatasubramanian et al., 2010)  vs combination of naïve and medication free for 
4 weeks (Lee and Kim, 2007) vs combination of naïve and minimally treated (ours)] 
as well as BMI and physical activity. To our knowledge this is the first study involving 
the evaluation of IGF-1 in UHR subjects. 
Collectively, our findings of a clear deviation in the circulating TNF-α, TNF-β, IFN-γ, IL-
4 of the FEP group and IL-4 of the UHR group from the HC, as opposed to the 
insignificant alteration to either cortisol or IGF-1 levels, provide another piece of 
evidence to the conundrum relating to the underlying pathophysiological 
mechanisms in psychosis as early as in FEP and UHR states. Yet, the findings should 
be interpreted with caution as they are not informative of their causality directions. 
Consequently, the authors acknowledge the need for more studies with longitudinal 
design and larger cohorts. 
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Figure 1. 
Mean of logarithmically transformed cytokines’ concentrations within the groups. IL: Interleukin; IFN: 
Interferon; TNF: Tumor Necrosis Factor; FEP: First Episode Psychosis; UHR: Ultra High Risk; HC: 
Healthy Control.  
 
 
  
Table 1. Legend 
UHR: Ultra High Risk for Psychosis; FEP: First Episode Psychosis; HC: Healthy Controls; Age, Education 
in years; BMI: body mass index; PANSS: Positive and Negative Syndrome Scale; PF: Positive Factor; NF: 
Negative Factor; GP: General Psychopathology;  TOTAL: Total score,IL: Interleukin; IFN: Interferon; 
TNF: Tumor Necrosis Factor; IGF: Insulin-like Growth Factor; cort-AUCg: cortisol Area Under Curve 
with respect to ground; Variables presented in mean (SD);only cytokines and IGF in median(25%,75% 
percentile). Cytokines levels in pg/ml, IGF-1 in ng/ml, cort-AUCg in μg/dl/min. Age, Education, BMI 
analyzed with one way ANOVA; smoking with x2; Cytokines, IGF-1 and cort-AUCg with Mann-Whitney 
tests with the p value corrected for multiple comparisons using the Bonferroni correction; *: target p 
set at <0.025 for an alpha of <0.05; (a): FEP vs HC; (b):UHR vs HC; IL-6 and IL-17A levels were under 
detection limits in >50% cases (data not shown).      
Table 1. Group demographics and clinical data–cytokines, IGF-1, cortisol levels 
 
  
  
  HC(n=23) UHR (n=12) FEP(n=25) Group comparison 
Demographics    p 
Age 27.04 (2.9) 24.5 (3.1) 25.48 (5.4) .199 
Education 13.26 (1.9) 13.16 (2.1) 12.44 (1.8) .307 
ΒΜΙ 24.52 (2.1) 24.15 (1.9) 24.8 (4.2) .832 
Smoking(Yes\No) 7/16 7/5 14/25 .138 
Clinical Assessment    p 
PANSS PF  4.92 (9.06) 18.64 (4.7) <.001 
PANSS NF  5.33 (9.78) 18.4 (4.2) .001 
PANSS GP  8.92 (16.27) 35.36 (5.37) <.001 
PANSS TOTAL  19.17 (34,75) 72.8 (11.2) .001 
 
Clinical Data 
   p 
IL-1β 68(44,82) 64 (40,67) 51(39,117) .959(a), .258(b) 
IL-2 97(93,101) 95 (94,97) 99(96,121) .065(a), .702(b) 
IL-4 68(68,70) 71(70,71) 71(69,76) .011(a*),.010(b*) 
IL-5 3.4(.4, 45.9) .4 (.4,3.8) 11.5(.4,53) .702(a), .172(b) 
IL-8 381(125,1168) 331 (0.2,1028) 218(35,694) .287(a), .402(b) 
IL-10 10(3,36) 6 (1,7) 19(4,55) .287(a), .115(b) 
IL-12p70 12(11,17) 11 (10,12) 14(11,23) .302(a), .273(b) 
IFN-γ 22(16,36) 20 (17,27) 39(23,122) .019(a*), .651(b) 
TNF-α .8(.8,4) .8(.8,.8) 9(.8,69.4) .018(a*), .276(b) 
TNF-β .6(.6,.6) .6(.6,.6) .6(.6,50) .017(a*), .252(b) 
IGF-1 5.56 (5.37, 5.72) 5.68 (5.4, 6.02) 5.57 (5.29, 5.84) .82(a), .259(b) 
Cort-AUCg 165.33(54.56) 206.4(72.85) 170.44(61.91) .934(a), .071(b) 
